Timothy A. Gregory, S. Knight, A. Aaroe, K. Highsmith, Zachary C. Janatpour, Barbara J O’Brien, Nazanin K. Majd, M. Loghin, Chirag Patel, S. Weathers, V. Puduvalli, C. Kamiya-Matsuoka
{"title":"胶质母细胞瘤患者感染 COVID-19 后肿瘤进展加快:一项回顾性病例对照研究","authors":"Timothy A. Gregory, S. Knight, A. Aaroe, K. Highsmith, Zachary C. Janatpour, Barbara J O’Brien, Nazanin K. Majd, M. Loghin, Chirag Patel, S. Weathers, V. Puduvalli, C. Kamiya-Matsuoka","doi":"10.1093/nop/npae029","DOIUrl":null,"url":null,"abstract":"\n \n \n We observed rapid tumor progression following COVID-19 infection among patients with glioblastoma and sought to systematically characterize their disease course in a retrospective case-control study.\n \n \n \n Using an institutional database, we retrospectively identified a series of COVID-19–positive glioblastoma cases and matched them by age and sex 1:2 to glioblastoma controls who had a negative COVID-19 test during their disease course. Demographic and clinical data were analyzed. Hyperprogression was defined using modified RECIST criteria. Time to progression and overall survival were estimated using the Kaplan-Meier method.\n \n \n \n Thirty-two glioblastoma cases with positive COVID-19 testing were matched to 64 glioblastoma controls with negative testing; age, sex, and molecular profiles did not differ between groups. Progression events occurred in 27 cases (84%) and 46 controls (72%). Of these, 14 cases (52%) presented with multifocal disease or leptomeningeal disease at progression compared with 10 controls (22%; p=0·0082). Hyperprogression was identified in 13 cases (48%) but only 4 controls (9%; p=0·0001). Cases had disease progression at a median of 35 days following COVID-19 testing, compared with 164 days for controls (p=0·0001). Median survival from COVID-19 testing until death was 8·3 months for cases but 17 months for controls (p=0·0016). Median overall survival from glioblastoma diagnosis was 20·7 months for cases and 24·6 months for controls (p=0·672).\n \n \n \n Patients with glioblastoma may have accelerated disease progression in the first 2 months after COVID-19 infection. Infected patients should be monitored vigilantly. Future investigations should explore tumor-immune microenvironment changes linking tumor progression and COVID-19.\n","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"28 7","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study\",\"authors\":\"Timothy A. Gregory, S. Knight, A. Aaroe, K. Highsmith, Zachary C. Janatpour, Barbara J O’Brien, Nazanin K. Majd, M. Loghin, Chirag Patel, S. Weathers, V. Puduvalli, C. Kamiya-Matsuoka\",\"doi\":\"10.1093/nop/npae029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n We observed rapid tumor progression following COVID-19 infection among patients with glioblastoma and sought to systematically characterize their disease course in a retrospective case-control study.\\n \\n \\n \\n Using an institutional database, we retrospectively identified a series of COVID-19–positive glioblastoma cases and matched them by age and sex 1:2 to glioblastoma controls who had a negative COVID-19 test during their disease course. Demographic and clinical data were analyzed. Hyperprogression was defined using modified RECIST criteria. Time to progression and overall survival were estimated using the Kaplan-Meier method.\\n \\n \\n \\n Thirty-two glioblastoma cases with positive COVID-19 testing were matched to 64 glioblastoma controls with negative testing; age, sex, and molecular profiles did not differ between groups. Progression events occurred in 27 cases (84%) and 46 controls (72%). Of these, 14 cases (52%) presented with multifocal disease or leptomeningeal disease at progression compared with 10 controls (22%; p=0·0082). Hyperprogression was identified in 13 cases (48%) but only 4 controls (9%; p=0·0001). Cases had disease progression at a median of 35 days following COVID-19 testing, compared with 164 days for controls (p=0·0001). Median survival from COVID-19 testing until death was 8·3 months for cases but 17 months for controls (p=0·0016). Median overall survival from glioblastoma diagnosis was 20·7 months for cases and 24·6 months for controls (p=0·672).\\n \\n \\n \\n Patients with glioblastoma may have accelerated disease progression in the first 2 months after COVID-19 infection. Infected patients should be monitored vigilantly. Future investigations should explore tumor-immune microenvironment changes linking tumor progression and COVID-19.\\n\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":\"28 7\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npae029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study
We observed rapid tumor progression following COVID-19 infection among patients with glioblastoma and sought to systematically characterize their disease course in a retrospective case-control study.
Using an institutional database, we retrospectively identified a series of COVID-19–positive glioblastoma cases and matched them by age and sex 1:2 to glioblastoma controls who had a negative COVID-19 test during their disease course. Demographic and clinical data were analyzed. Hyperprogression was defined using modified RECIST criteria. Time to progression and overall survival were estimated using the Kaplan-Meier method.
Thirty-two glioblastoma cases with positive COVID-19 testing were matched to 64 glioblastoma controls with negative testing; age, sex, and molecular profiles did not differ between groups. Progression events occurred in 27 cases (84%) and 46 controls (72%). Of these, 14 cases (52%) presented with multifocal disease or leptomeningeal disease at progression compared with 10 controls (22%; p=0·0082). Hyperprogression was identified in 13 cases (48%) but only 4 controls (9%; p=0·0001). Cases had disease progression at a median of 35 days following COVID-19 testing, compared with 164 days for controls (p=0·0001). Median survival from COVID-19 testing until death was 8·3 months for cases but 17 months for controls (p=0·0016). Median overall survival from glioblastoma diagnosis was 20·7 months for cases and 24·6 months for controls (p=0·672).
Patients with glioblastoma may have accelerated disease progression in the first 2 months after COVID-19 infection. Infected patients should be monitored vigilantly. Future investigations should explore tumor-immune microenvironment changes linking tumor progression and COVID-19.
期刊介绍:
ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications.
The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.